Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Cefepime-zidebactam · Cefepime, Cefepime Hydrochloride And Dextrose

Small molecule · Inhibitor of bacterial cell wall · developed by Wockhardt Bio

Approved FDA, May 2026

1 Registered trials

What is Cefepime-zidebactam?

Cefepime-zidebactam is a combination of cefepime, a cephalosporin antibacterial, and zidebactam, a beta-lactamase inhibitor and non-beta-lactam antibacterial.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Cefepime, Cefepime Hydrochloride And Dextrose, Zaynich
Drug type: Small molecule
Targets: bacterial cell wall
Mechanism: Inhibitor of bacterial cell wall
Therapy area: Infectious disease
Developer: Wockhardt Bio Ag
In trials of: MEDP
FDA status: Approved as Cefepime, Cefepime Hydrochloride And Dextrose, Zaynich (May 29, 2026), NDA220787 · FDA label

✅ FDA-approved uses

Complicated urinary tract infections including pyelonephritis (Zaynich)

From the indications section of the FDA label (version of Jun 5, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04979806	Phase 3	Complicated Urinary Tract Infection	Completed	MEDP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute PyelonephritisComplicated Urinary Tract Infection

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z